Nanna Albæk

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Roche Innovation Center Copenhagen A/s. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nanna Albæk. Retrieved from https://idiyas.com/inventor/nanna-albæk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 16(Granted Patents)

Company Filing History:

7 out of 46

Roche Innovation Center Copenhagen A/s

patents

Years Active: 2018-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421516 - Antisense oligomers targeting PCSK9 (2025-09-23),

2. 11739332 - Antisense oligomers targeting PCSK9 (2023-08-29),

3. 11091764 - Antisense oligomers targeting PCSK9 (2021-08-17),

4. 10443058 - Antisense oligomers targeting PCSK9 (2019-10-15),

5. 10385342 - Methods of treatment using antisense oligomers and conjugates targeting PCSK9 (2019-08-20),

6. 10370668 - Manufacture of antisense oligomers and conjugates targeting PCSK9 (2019-08-06),

7. 9879265 - Oligonucleotide conjugates (2018-01-30),

Title: Nanna Albæk: Innovator in Antisense Oligomers

Introduction

Nanna Albæk is a prominent inventor based in Hørsholm, Denmark. She has made significant contributions to the field of biotechnology, particularly in the development of antisense oligomers. With a total of 7 patents to her name, her work focuses on addressing critical medical disorders.

Latest Patents

One of Nanna Albæk's latest patents involves antisense oligomers targeting Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). This invention relates to oligomeric compounds and conjugates that target PCSK9 mRNA within cells. By reducing the expression of PCSK9, her invention holds promise for treating various medical disorders, including hypercholesterolemia and related conditions.

Career Highlights

Throughout her career, Nanna has worked with notable organizations such as Roche Innovation Center Copenhagen A/S and F. Hoffmann-La Roche AG. Her experience in these leading companies has allowed her to advance her research and contribute to innovative solutions in the medical field.

Collaborations

Nanna has collaborated with esteemed colleagues, including Maj Hedtjärn and Niels Fisker Nielsen. These partnerships have further enriched her work and expanded the impact of her inventions.

Conclusion

Nanna Albæk's contributions to the field of biotechnology through her innovative patents demonstrate her commitment to improving medical treatments. Her work in antisense oligomers targeting PCSK9 is a testament to her expertise and dedication to advancing healthcare solutions.

Profile summary based on public USPTO records.